Drugs / Golcadomide
Golcadomide
also known as
CC-99282 · BMS-986369-05 · BMS-986369-05, CC-99282 · CC-99282 HYDROCHLORIDE · CC1007548 · Golcadomida · Golcadomide (GOLCA; CC-99282) · GOLCADOMIDE HYDROCHLORIDE
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07763418 | Sep → Dec 2026 expected | chronic renal failure syndrome | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT07608731 | Jun 2026 → Apr 2029 expected | diffuse large B-cell lymphoma of the central nervous system, large B-cell lymphoma | Allison Winter | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06363630 | Apr → Aug 2024 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06209619 | Jan 2024 → Dec 2026 expected | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Nathan Denlinger | Recruiting | No outcome recorded |
| Phase 1 | NCT05169515 | Oct 2022 → Sep 2029 expected | B-cell non-Hodgkin lymphoma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1 | NCT04884035 | Sep 2021 → Dec 2028 expected | B-cell non-Hodgkin lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04434196 | Dec 2020 → May 2024 | non-Hodgkin lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07578077 | Dec 2026 → Apr 2030 expected | mantle cell lymphoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07269639 | Jan 2026 → Dec 2027 expected | large B-cell lymphoma | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07018752 | Aug 2025 → Apr 2028 expected | peripheral T-cell lymphoma, not otherwise specified | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06767956 | Jun 2025 → Apr 2027 | non-Hodgkin lymphoma | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06090539 | Dec 2023 → Oct 2027 expected | non-Hodgkin lymphoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03930953 | May 2019 → Apr 2027 expected | non-Hodgkin lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03310619 | Dec 2017 → Feb 2023 | diffuse large B-cell lymphoma, follicular lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06835530 | Apr 2025 → Apr 2030 expected | diffuse large B-cell lymphoma | Fondazione Italiana Linfomi - ETS | Recruiting | No outcome recorded |
| Phase 2 | NCT06834373 | Apr 2025 → Jun 2027 expected | ALK-positive large B-cell lymphoma, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type +7 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06425302 | Aug 2024 → Nov 2026 expected | follicular lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06271057 | Jun 2024 → Mar 2027 expected | monofixation syndrome, primary mediastinal large B-cell lymphoma, relapsed/refractory diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 2 | NCT06108232 | Mar 2024 → Dec 2027 expected | follicular lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05788081 | Aug 2023 → Jan 2027 expected | follicular lymphoma | Olivia Newton-John Cancer Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05283720 | Jun 2022 → Nov 2032 expected | non-Hodgkin lymphoma | Genmab | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06911502 | Jul 2025 → Apr 2028 expected | follicular lymphoma | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06356129 | Jun 2024 → Aug 2027 expected | large B-cell lymphoma | Celgene Corporation | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-12-08 | Bristol-Myers Squibb | Results Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025 bms.com ↗
At median follow-up of 24 months, golcadomide 0.4 mg plus R-CHOP continued to demonstrate deep, durable responses and promising progression-free survival (PFS). |
| 2025-12-01 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio bms.com ↗
First-in-class lymphoma CELMoD™ agent, golcadomide, delivers durable responses in combinations across aggressive and indolent lymphomas |
| 2025-06-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 bms.com ↗
updated clinical findings on the company’s investigational oral CELMoD™ agents mezigdomide and iberdomide in multiple myeloma, and golcadomide in non-Hodgkin lymphoma |
| 2024-11-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms bms.com ↗
new analyses from Phase 1b DLBCL-001 study showing golcadomide plus R-CHOP has high minimal residual disease (MRD) negativity in high-risk 1L LBCL |
| 2024-05-23 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms bms.com ↗
New Phase 1/2 data from the targeted protein degradation platform including the novel oral CELMoD agents iberdomide in newly diagnosed multiple myeloma, mezigdomide in relapsed/refractory multiple myeloma, and golcadomide in first-line LBCL and relapsed/refractory FL, reinforcing promising activity. |
| 2023-12-11 | Bristol-Myers Squibb | Results Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023 bms.com ↗
Bristol Myers Squibb (NYSE: BMY) announced the results of two early studies evaluating combinations of potential first-in-class CELMoD™ agent golcadomide in non-Hodgkin lymphomas. |
| 2022-05-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders bms.com ↗
Data from Phase 1 studies of CC-99282, a cereblon E3 ligase modulator (CELMoD ® ) agent, and CC-95251, an anti-signal regulatory protein-alpha (SIRPα) antibody combined with rituximab, show promising activity in patients with relapsed or refractory non-Hodgkin lymphoma (EHA). |
All press releases naming this drug 7 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | golcadomide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06271057 ↗ |
| Known as | BMS-986369-05 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | BMS-986369-05, CC-99282 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | CC-99282 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03310619 ↗ |
| Known as | CC-99282 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | CC1007548 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | Golcadomida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Known as | Golcadomide (GOLCA; CC-99282) | “Golcadomide (GOLCA; CC-99282)” NCT06767956 ↗ |
| Known as | GOLCADOMIDE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095226 ↗ |
| Modality | Other / unclassified | “golcadomide (CELMoD)” NCT06271057 ↗ |
| Route | Oral | “Orally Available Small Molecule, CC-99282” NCT03930953 ↗ |